Close Menu

NEW YORK (GenomeWeb) – Roche has ended its development, commercialization, and licensing agreement with Pacific Biosciences, according to documents filed with the US Securities and Exchange Commission. The termination will go into effect on Feb. 10, 2017.

The announcement of the termination hit PacBio's stock hard, sending the firm's shares down 40 percent to $4.11 in late Thursday morning trade on the Nasdaq.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Dec
02
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

Dec
10
Sponsored by
Congenica II

This webinar will discuss the use of next-generation sequencing and an optimized variant interpretation workflow to increase diagnostic yield in complex clinical cases.